Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

New Drug Triggers Liver Regeneration After Surgery

By BiotechDaily International staff writers
Posted on 25 Aug 2014
Print article
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).
Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice.

Liver cancer often results in a loss of blood flow, and consequently, oxygen and nutrients to the liver tissue, resulting in deteriorating liver function. Although the diseased part of the liver can often be surgically removed, the sudden restoration of blood flow to the remaining liver tissue can trigger inflammation—a process called ischemia reperfusion injury (IRI). IRI occurs partly from the deposition of immune proteins called complement on the surface of liver cells, causing them to die and thereby impairing liver regeneration.

Complement inhibitors effectively suppress IRI, but the benefits of this approach come at a cost, because specific complement proteins are also required for liver tissue to regrow. According to scientists from the Medical University of South Carolina (MUSC; Charleston, USA), the novel inhibitor suppressed the deposition of complement proteins and promoted the division of new liver cells. Even after removal of as much as 90% of the liver, treatment increased survival from 0% in untreated animals to an impressive 70%. The study’s findings were published August 11, 2014, in the Journal of Experimental Medicine.

The selectivity of this unique complement inhibitor, and its unforeseen ability to enhance liver regeneration, suggests that it might represent a new treatment strategy for a range of liver injuries in humans, according to the researchers.

Related Links:

Medical University of South Carolina



Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.